Cargando…

On a collision course: SARS-CoV-2 variants and CAR T cells

Detalles Bibliográficos
Autor principal:	Auletta, Jeffery J.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	The American Society of Hematology 2023
Materias:	Inside Blood Advances
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10262728/ https://www.ncbi.nlm.nih.gov/pubmed/37310762 http://dx.doi.org/10.1182/bloodadvances.2023010371

Ejemplares similares

This CAR won’t start: predicting nonresponse in ALL
por: Webster, Jonathan A., et al.
Publicado: (2023)

Comorbidities in DLBCL: too "Severe4" CAR-T therapy?
por: Qualls, David, et al.
Publicado: (2023)

More evidence for low-dose IL-2 for chronic GVHD in children
por: Levine, John E.
Publicado: (2023)

Diagnosing TMAs by automated red cell morphology analyses
por: Billett, Henny H., et al.
Publicado: (2023)

Blood stem cell grafts: frozen is fine, but fresh is best
por: Horwitz, Mitchell E.
Publicado: (2023)

Buckling up against COVID-19 after CAR T-cell therapy
por: Auletta, Jeffery J.
Publicado: (2022)

Cord blood power and the definition of success after BMT
por: Boelens, Jaap Jan, et al.
Publicado: (2022)

Small but mighty: T-replete cords for myeloid disease
por: LaBelle, James L.
Publicado: (2023)

Curing CLL: one clone at a time
por: Aslan, Burcu, et al.
Publicado: (2022)

The sweet taste of liberalizing dietary restrictions in HCT
por: Peled, Jonathan U., et al.
Publicado: (2023)

Further evidence supporting the global use of hydroxyurea
por: Archer, Natasha M.
Publicado: (2023)

Peripheral megakaryocytes sound the alarm in COVID-19
por: Boilard, Eric, et al.
Publicado: (2023)

Haplo ever after: haplo PTCy for children
por: Talano, Julie-An, et al.
Publicado: (2023)

Histidine-rich glycoprotein: antithrombosis without bleeding
por: Schmaier, Alvin H.
Publicado: (2023)

Natalizumab for GVHD: too little or too late?
por: Quann, Kevin, et al.
Publicado: (2023)

ADP: the missing link between thrombosis and hemolysis
por: Gerber, Gloria F., et al.
Publicado: (2023)

A wholesale approach to disarm multiple myeloma
por: Cenci, Simone
Publicado: (2023)

Autologous transplant and second malignancies in MM
por: Pasvolsky, Oren, et al.
Publicado: (2023)

It’s high time to turn the spotlight on HbSC disease
por: Oluwole, Olubusola, et al.
Publicado: (2023)

ICANS prophylaxis: potentially transformative but elusive
por: Dowling, Mark R., et al.
Publicado: (2023)

HTLV-1 infection: role of CTL efficiency
por: Bangham, Charles R. M.
Publicado: (2008)

Response to SARS-CoV-2 vaccination in patients after hematopoietic cell transplantation and CAR T-cell therapy
por: Dhakal, Binod, et al.
Publicado: (2021)

Hemophagocytic lymphohistiocytosis in SARS-CoV-2 infection
por: Dewaele, Klaas, et al.
Publicado: (2020)

Morphological changes in a case of SARS-CoV-2 infection
por: Jones, John R., et al.
Publicado: (2020)

SARS-CoV-2 vaccination and immune thrombotic thrombocytopenic purpura
por: Shah, Hridaya, et al.
Publicado: (2022)

Vaccine-induced T-cell responses against SARS-CoV-2 and its Omicron variant in patients with B cell–depleted lymphoma after CART therapy
por: Atanackovic, Djordje, et al.
Publicado: (2022)

Efficacy of tixagevimab-cilgavimab in preventing SARS-CoV-2 for patients with B-cell malignancies
por: Davis, James A., et al.
Publicado: (2023)

Anti-CD38 therapy impairs SARS-CoV-2 vaccine response against alpha and delta variants in patients with multiple myeloma
por: Henriquez, Soledad, et al.
Publicado: (2022)

Ritonavir- and lopinavir-induced eryptosis in a SARS-CoV-2–infected patient
por: Stalder, Gregoire, et al.
Publicado: (2020)

Leukoerythroblastosis and plasmacytoid lymphocytes in a child with SARS-CoV-2–associated multisystem inflammatory syndrome
por: Lee, Won Sok, et al.
Publicado: (2020)

Antibody response after 2 and 3 doses of SARS-CoV-2 mRNA vaccine in allogeneic hematopoietic cell transplant recipients
por: Maillard, Alexis, et al.
Publicado: (2022)

Neutralization of SARS-CoV-2 Omicron after vaccination of patients with myelodysplastic syndromes or acute myeloid leukemia
por: Bellusci, Lorenza, et al.
Publicado: (2022)

New blood donors in times of crisis: Increased donation willingness, particularly among people at high risk for attracting SARS‐CoV‐2
por: Spekman, Marloes L. C., et al.
Publicado: (2021)

Post–SARS-CoV-2 vaccination acute hemolysis in an older man: don’t forget to look at the blood smear
por: Duchemann, Boris, et al.
Publicado: (2021)

No evidence of SARS-CoV-2 transfusion transmission despite RNA detection in blood donors showing symptoms after donation
por: Cappy, Pierre, et al.
Publicado: (2020)

Hybrid immunity in immunocompromised patients with CLL after SARS-CoV-2 infection followed by booster mRNA vaccination
por: Blixt, Lisa, et al.
Publicado: (2022)

Waning of SARS-CoV-2 RBD antibodies in longitudinal convalescent plasma samples within 4 months after symptom onset
por: Perreault, Josée, et al.
Publicado: (2020)

Surrogate test performance for SARS‐CoV‐2 neutralizing antibodies (nAbs) for convalescent plasma (CCP): How useful could they be?
por: Wendel, Silvano, et al.
Publicado: (2021)

Booster BNT162b2 optimizes SARS-CoV-2 humoral response in patients with myeloma: the negative effect of anti-BCMA therapy
por: Terpos, Evangelos, et al.
Publicado: (2022)

Premature aging of the immune system affects the response to SARS-CoV-2 mRNA vaccine in β-thalassemia: role of an additional dose
por: Carsetti, Rita, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_seeq4e010rdk29r77693mc7eim